May 2019 - Belgian biotechnology company ViroVet will partner with Researchers at The Pirbright Institute to develop the first antiviral drugs that act against African swine fever (ASF).

African Swine Fever

Jan 2018 - ViroVet is proud to announce that it has been presented with the best start-up of the year accolade for the second time. Two years ago, the company was awarded for its concept and ideas, this time the jury bestowed the company for its progress and its ability to raise capital.

Awarded

Jan 2017 - ViroVet is proud to announce that Dr George Gunn joined its board of directors. Dr Gunn was CEO of Novartis Animal Health and a member of the global executive committee of Novartis until early 2015.Before joining Novartis in 2003, he worked with the UK's Ministry of Agriculture, Fisheries and Food in the 1970s and 1980s and held various functions in the Animal Health Industry from head of Janssen Animal Health in the UK in 1996 up to president of Pharmacia Animal Health in the early 2000s. He received the Animal Pharm Lifetime Achievement Award in January 2017.

Chairman

Oct 2018 - ViroVet has won the Pre-Slush pitching competition organised by PwC. The finalists of the pitching competition had just 3 minutes each to convince the jury and the audience about the innovative aspects and scalability of their business concept and/or technology. The winner goes to Slush in Helsinki.

Winners

Oct 2017 - ViroVet, a leading Belgian biopharmaceutical company active in the development of innovative vaccines and antiviral drugs for livestock, is proud to announce that it has attracted Capricorn Venture Partners to conclude the second closing of its series A financing round, raising another 1.5 million euro. The financing will be used to further develop and launch its veterinary product portfolio.

New investor

Dec 2016 - ViroVetis proud to announce that it has successfully concluded the first closing of its series A financing round, raising 5 million euro. The financing will be used to further develop and launch its veterinary product portfolio. The investment was led by PMV (through Biotech Fund Flanders) and the Agri Investment Fund, with participations from the Gemma Frisius Fund KU Leuven, Vives II and Aratana Therapeutics NV.

Capital

Sep 2018 - ViroVet announced today that it has received a 590k€ grant from Flanders Innovation & Entrepreneurship (VLAIO) to assess the potential of its PLLAV-vaccination technology in poultry and large ruminants.

Granted

May 2017 - ViroVet, a leading Belgian biopharmaceutical company active in the development of innovative vaccines and antiviral drugs for livestock, is proud to announce a collaboration with GALVmed. Under the collaboration, ViroVet will extend its vaccine pipeline to include novel vaccines for small ruminants.

GALVmed

Jan 2016 - By Animal Pharm News: "The accolade of best start-up company for 2015 went to ViroVet. The Leuven-based company is a spin-out from US pet pharmaceutical developer Aratana Therapeutics. ViroVet is one of the only young veterinary medicine companies developing molecules for large unmet needs in livestock."

Awarded